BACKGROUND: Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate. CASE PRESENTATION: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years. Despite improvement of bone density, she experienced a low truama femoral shaft fracture. CONCLUSION: This case shows a rare complication of treatment by alendronate. It may be needed to evaluate patients with long term usage of bisphosphonates for cortical thickness.
BACKGROUND:Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate. CASE PRESENTATION: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years. Despite improvement of bone density, she experienced a low truama femoral shaft fracture. CONCLUSION: This case shows a rare complication of treatment by alendronate. It may be needed to evaluate patients with long term usage of bisphosphonates for cortical thickness.
Authors: Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich Journal: J Orthop Trauma Date: 2008 May-Jun Impact factor: 2.512
Authors: Michael McClung; Steven T Harris; Paul D Miller; Douglas C Bauer; K Shawn Davison; Larry Dian; David A Hanley; David L Kendler; Chui Kin Yuen; E Michael Lewiecki Journal: Am J Med Date: 2012-11-20 Impact factor: 4.965
Authors: Seo Young Kim; Sebastian Schneeweiss; Jeffrey N Katz; Raisa Levin; Daniel H Solomon Journal: J Bone Miner Res Date: 2011-05 Impact factor: 6.741